Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Short term Debt (2021 - 2023)

bioAffinity Technologies has reported Short term Debt over the past 3 years, most recently at $42334.0 for Q2 2023.

  • Quarterly Short term Debt changed N/A to $42334.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $42334.0 through Jun 2023, changed N/A year-over-year, with the annual reading at $251746.0 for FY2022, 383.44% up from the prior year.
  • Short term Debt was $42334.0 for Q2 2023 at bioAffinity Technologies, down from $168430.0 in the prior quarter.
  • Over five years, Short term Debt peaked at $500000.0 in Q3 2022 and troughed at $42334.0 in Q2 2023.
  • The 3-year median for Short term Debt is $168430.0 (2023), against an average of $202916.8.
  • The largest YoY upside for Short term Debt was 383.44% in 2022 against a maximum downside of 383.44% in 2022.
  • A 3-year view of Short term Debt shows it stood at $52074.0 in 2021, then surged by 383.44% to $251746.0 in 2022, then plummeted by 83.18% to $42334.0 in 2023.
  • Per Business Quant, the three most recent readings for BIAF's Short term Debt are $42334.0 (Q2 2023), $168430.0 (Q1 2023), and $251746.0 (Q4 2022).